Evidence map›Paper›PMID 32872343›Full record

ArticleBiomolecules2020

Identification and Target-Modification of SL-BBI: A Novel Bowman-Birk Type Trypsin Inhibitor from

Xi Chen, Dong Chen, Linyuan Huang, Xiaoling Chen, Mei Zhou, Xinping Xi, Chengbang Ma, Tianbao Chen, Lei Wang

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Antibacterial action mechanisms and mode of trypsin inhibitors: a systematic review.Journal of enzyme inhibition and medicinal chemistry · 2022
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xi ChenNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Dong ChenNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Linyuan HuangSchool of Life Sciences and Technology, China Pharmaceutical University, Nanjing 211198, China.
Xiaoling ChenNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Mei ZhouNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0003-2576-0252
Xinping XiNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Chengbang MaNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Tianbao ChenNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0001-8011-9260
Lei WangNatural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-8811-8489
Queen's University Belfast · GBChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The peptides from the ranacyclin family share similar active disulphide loop with plant-derived Bowman-Birk type inhibitors, some of which have the dual activities of trypsin inhibition and antimicrobial. Herein, a novel Bowman-Birk type trypsin inhibitor of the ranacyclin family was identified from the skin secretion of broad-folded frog (

Indexed as

Amino Acid MotifsAnimalsAnti-Infective AgentsAntineoplastic AgentsApoptosisCell Line, TumorChymotrypsinDrug Screening Assays, AntitumorHemolytic AgentsHumansLung NeoplasmsMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureRanidaeTrypsin InhibitorsAnti-Infective AgentsAntineoplastic AgentsChymotrypsinHemolytic AgentsTrypsin InhibitorsanticancerantimicrobialBowman–Birk type inhibitornatural moleculesranacyclin

Identifiers

PMID32872343
PMCPMC7565067
OpenAlexW3082290577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.